Reducing mortality from 2019-nCoV: host-directed therapies should be an option
- 5 February 2020
- journal article
- letter
- Published by Elsevier BV in The Lancet
- Vol. 395 (10224), e35-e36
- https://doi.org/10.1016/s0140-6736(20)30305-6
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Advances in respiratory virus therapeutics - A meeting report from the 6th for isirv Antiviral Group conferenceAntiviral Research, 2019
- Clinically Relevant Immune Responses against Cytomegalovirus: Implications for Precision MedicineInternational Journal of Molecular Sciences, 2019
- Cell therapy in acute respiratory distress syndromeJournal of Thoracic Disease, 2018
- Immune therapy in sepsis: Are we ready to try again?Journal of the Intensive Care Society, 2018
- Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathologySeminars in Immunopathology, 2017
- Coronaviruses — drug discovery and therapeutic optionsNature Reviews Drug Discovery, 2016
- Host-directed therapies for improving poor treatment outcomes associated with the middle east respiratory syndrome coronavirus infectionsInternational Journal of Infectious Diseases, 2015
- The long‐term impact of severe acute respiratory syndrome on pulmonary function, exercise capacity and health statusRespirology, 2010
- Effect of Oral Gavage Treatment with ZnAL42 and other Metallo-Ion Formulations on Influenza a H5N1 and H1N1 Virus Infections in MiceAntiviral Chemistry and Chemotherapy, 2007
- The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitorProceedings of the National Academy of Sciences of the United States of America, 2003